Format

Send to

Choose Destination
Gastroenterology. 2012 Feb;142(2):219-32. doi: 10.1053/j.gastro.2011.12.001. Epub 2011 Dec 8.

Dysregulation of Wnt/β-catenin signaling in gastrointestinal cancers.

Author information

1
Science and Technology Program, University of Washington Bothell, Bothell, Washington, USA. bdwhite@u.washington.edu

Abstract

Aberrant Wnt/β-catenin signaling is widely implicated in numerous malignancies, including cancers of the gastrointestinal tract. Dysregulation of signaling is traditionally attributed to mutations in Axin, adenomatous polyposis coli, and β-catenin that lead to constitutive hyperactivation of the pathway. However, Wnt/β-catenin signaling is also modulated through various other mechanisms in cancer, including cross talk with other altered signaling pathways. A more complex view of Wnt/β-catenin signaling and its role in gastrointestinal cancers is now emerging as divergent phenotypic outcomes are found to be dictated by temporospatial context and relative levels of pathway activation. This review summarizes the dysregulation of Wnt/β-catenin signaling in colorectal carcinoma, hepatocellular carcinoma, and pancreatic ductal adenocarcinoma, with particular emphasis on the latter two. We conclude by addressing some of the major challenges faced in attempting to target the pathway in the clinic.

PMID:
22155636
PMCID:
PMC3285553
DOI:
10.1053/j.gastro.2011.12.001
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center